Literature DB >> 31418638

Implementing group visits for opioid use disorder: A case series.

Randi Sokol1, Mark Albanese2, Chiara Albanese3, Gerard Coste4, Ellie Grossman2, Diana Morrill5, David Roll4, Amy Sobieszczyk4, Zev Schuman-Olivier2.   

Abstract

Background: Group-based models of Office-Based Opioid Treatment with buprenorphine-naloxone (B/N) are increasingly being implemented in clinical practice to increase access to care and provide additional therapeutic benefits. While previous studies reported these Group-Based Opioid Treatment (GBOT) models are feasible for providers and acceptable to patients, there has been no literature to help providers with the more practical aspects of how to create and maintain GBOT in different outpatient settings. Case series: We present 4 cases of GBOT implementation across a large academic health care system, highlighting various potential approaches for providers who seek to implement GBOT and demonstrate "success" based on feasibility and sustainability of these models. For each case, we describe the pros and cons and detail the personnel and resources involved, patient mix and group format, workflow logistics, monitoring and management, and sustainability components. Discussion: The implementation details illustrate that there is no one-size-fits-all approach, although feasibility is commonly supported by a team-based, patient-centered medical home. This approach includes the capacity for referral to higher levels of mental health and addiction support services and is bolstered by ongoing provider communication and shared resources across the health system. Future research identifying the core and malleable components to implementation, their evidence base, and how they might be influenced by site-specific resources, culture, and other contextual factors can help providers better understand how to implement a GBOT model in their unique clinical environment.

Entities:  

Keywords:  Buprenorphine-naloxone; GBOT; case series; group psychotherapy; group visit; implementation science; shared medical appointment

Year:  2019        PMID: 31418638      PMCID: PMC7440777          DOI: 10.1080/08897077.2019.1635958

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  24 in total

1.  Clinical supervision, emotional exhaustion, and turnover intention: a study of substance abuse treatment counselors in the Clinical Trials Network of the National Institute on Drug Abuse.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2008-12

Review 2.  Unobserved "home" induction onto buprenorphine.

Authors:  Joshua D Lee; Frank Vocci; David A Fiellin
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

3.  Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.

Authors:  Joji Suzuki; Jennifer Zinser; Brenda Klaiber; Melanie Hannon; Hope Grassi; Madeline Spinosa; Altagracia Ramirez; Mohammed Issa; Siu Ping Chin Feman
Journal:  Subst Abus       Date:  2015       Impact factor: 3.716

Review 4.  The Next Stage of Buprenorphine Care for Opioid Use Disorder.

Authors:  Stephen A Martin; Lisa M Chiodo; Jordon D Bosse; Amanda Wilson
Journal:  Ann Intern Med       Date:  2018-10-23       Impact factor: 25.391

Review 5.  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.

Authors: 
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

6.  Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.

Authors:  Colleen T LaBelle; Steve Choongheon Han; Alexis Bergeron; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2015-06-26

7.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Authors:  Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

8.  Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial.

Authors:  Sarah Bowen; Katie Witkiewitz; Seema L Clifasefi; Joel Grow; Neharika Chawla; Sharon H Hsu; Haley A Carroll; Erin Harrop; Susan E Collins; M Kathleen Lustyk; Mary E Larimer
Journal:  JAMA Psychiatry       Date:  2014-05       Impact factor: 21.596

9.  Patient satisfaction with primary care office-based buprenorphine/naloxone treatment.

Authors:  Declan T Barry; Brent A Moore; Michael V Pantalon; Marek C Chawarski; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

10.  Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.

Authors:  Theresa A Rowe; Janet S Jacapraro; Darius A Rastegar
Journal:  Addict Sci Clin Pract       Date:  2012-10-29
View more
  3 in total

1.  Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model.

Authors:  Jonathan E Fried; Sanjay Basu; Russell S Phillips; Bruce E Landon
Journal:  Ann Fam Med       Date:  2020-11       Impact factor: 5.166

2.  A qualitative investigation of addiction counselors' perceptions and experiences implementing an open-access model for treating opioid use disorder.

Authors:  Lindsay M S Oberleitner; Lynn M Madden; Dharushana Muthulingam; Ruthanne Marcus; David E Oberleitner; Mark Beitel; Marina Gaeta; Joseph F Tamberelli; Declan T Barry
Journal:  J Subst Abuse Treat       Date:  2020-11-02

3.  Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study.

Authors:  Thomas Fatkin; Sarah K Moore; Kayley Okst; Timothy B Creedon; Farah Samawi; Alaine Kiera Fredericksen; David Roll; Alexandra Oxnard; Benjamin Lê Cook; Zev Schuman-Olivier
Journal:  J Subst Abuse Treat       Date:  2021-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.